Five-year follow-up from the INTREPID trial confirms that subthalamic nucleus deep brain stimulation significantly improves motor symptoms, reduces dyskinesia, lowers medication needs, and enhances daily living activities in moderate to advanced Parkinson disease patients, with an acceptable safety profile.